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What is new? 50  Study power in clinical trials is low: 7% of trials were sufficiently powered (≥0.8) and 51 14% had a power above 0.5; within significant meta-analyses 12% was sufficiently 52 powered and 24% had a power above 0.5.
53
 Study power has increased from 5% in [1975] [1976] [1977] [1978] [1979] to 9% in 2010-2014. 54  Average effect sizes are small and did not increase over time. The practice of conducting scientific studies with low statistical power has been consistently 59 criticized across academic disciplines [1] [2] [3] [4] [5] . Statistical power is the probability that a study will 60 detect an effect when there is a true effect to be detected. Underpowered studies have a low 
Materials and Methods

74
Data were extracted and calculated from trials included in published reviews from the second 75 Issue of the 2017 Cochrane database of systematic reviews. Cochrane reviews only include meta-76 analyses if the methodology and outcomes of the included trials are comparable across study 77 populations. Meta-analysis data is available for download in standardized XML-format for those 78 with an institutional Cochrane Library license. We provide open-source software to convert these 79 data and reproduce our entire processing pipeline 13 .
80
Trials were selected if they were published after 1974 and if they were included in a meta-81 analysis based on at least five trials. Since relatively few studies from 2015-2017 were included 82 in our meta-analyses, these years were excluded. For each individual clinical trial, publication 83 year, outcome estimates (odds or risk ratio, risk difference or standardized mean difference) and 84 group sizes were extracted. For the main analyses all meta-analyses were used; sub-analyses 85 were performed on only the meta-analyses with a reported p-value below 0.05, irrespective of the 86 p-value of the individual trial. For meta-analyses reporting standardized mean differences 87 (Cohen's d), the reported meta-analytic effect size was used to compute individual study power.
88
For meta-analyses reporting dichotomous outcomes, meta-analytic effect size (Cohen's h) was 89 computed using arcsine transformation of proportions 12 . The main analysis used the effect size 90 extracted from the meta-analysis, which was performed as either fixed-, or random-effects as 91 judged by the authors of that specific Cochrane review. As a sensitivity analysis we recomputed 92 the meta-analytic effect size using fixed effects, random effects, and unrestricted weighted least 93 squares/ weighed average of the adequately powered (WLS-WAAP) 14 . This latter method was 94 developed to optimize results from meta-analysis in the context of selective reporting bias: WLS-95 WAAP performs better than both fixed and random effects analyses in the context of publication 96 bias, allows to correct for heterogeneity, and gives similar results to fixed effects when both are 97 not present 14, 15 . Study power was computed in R using the 'pwr' package 16 . Following 98 minimum recommendations for the statistical power of studies 12 , comparisons with a power 99 above or equal to 80% were considered to be sufficiently powered. Study power, group sizes and 100 effect sizes over time were summarised and visualized for all clinical trials. 
Results
102
Data from 136,212 clinical trials were available, from 11,852 meta-analyses in 1,918 Cochrane 103 reviews. Of these, 77,947 trials (57.2%) were from a meta-analysis with an overall p-value below 104 0.05, from 5,903 meta-analyses (49.8%) in 1,411 Cochrane reviews (73.6%). In the original 105 systematic reviews fixed effects were used in 55% of meta-analyses whereas 45% used random 106 effects. Of all trials 7.3% had a statistical power of at least 80% (the recommended minimum 12 , 107 which we shall denote as 'sufficient power') to detect an effect size as large as the meta-analysed 108 effect size; for the subset of significant meta-analyses this was 12.4%. The median power 109 (interquartile range, IQR) was 9% (95% confidence interval (CI) 6-26%), which was 20% (10-110 48%) for significant meta-analysis (Table 1) . Table   134 2; these remained stable over time ( Figure 2 ). The standardized effect sizes were small, with a 135 median Cohen's h of 0.09 (0.04-0.22) and a median Cohen's d of 0.20 (0.11-0.40) ( Table 2) ; 136 Figure 3 shows the distribution plots for these two measures; for the significant meta-analyses 137 the median effect sizes were higher (Supplementary Table 1 and Supplementary Figure 4 ).
138
Sensitivity analyses showed robust results regardless of the method for performing meta-139 analysis. The proportion of studies with sufficient power was between 7.2% and 7.5% depending 140 on the method; the median power remained 9% across methods ( Supplementary Table 2 ). Years with less than ten studies with the specific measure were omitted from the plot. Median effect sizes are computed based on the meta-analysis; every meta-analysis is taken into account once irrespective of the number of included trials. To obtain a meaningful summary statistic, effect sizes were transformed to be unidirectional: the absolute number of risk differences and standardized mean differences was taken, and for (Peto) odds ratios and risk ratio's effects below one were inversed (1 divided by the effect, e.g. an RR of 0.5 becomes 2.0). These transformations only studies, or the exclusion of meta-analyses with less than five trials.
180
Our use of meta-analytic effect sizes to compute study power has two important shortcomings.
181
First, although it is a fair -and the only available-approximation of the true effect of a given 182 therapy, power and sample size calculations are designed to be performed a-priori. We would 183 fully endorse that for an individual study there is no space for a post-hoc power computation.
184
Second, it may be questioned whether statistical power can be computed when the estimation of 185 the effect size includes a null-effect in the 95% confidence interval. If there is no effect, a power 186 calculation cannot be performed. If the null-hypothesis: "there is no effect" cannot be rejected, 187 there is no clear effect size estimation available as the basis for the power calculation. We have 188 therefore also included all results for the subset of significant meta-analyses.
189
By analysing the temporal pattern across four decades, we identified an increase of study power the aim of performing either a multi-centre study or a prospective meta-analysis may also 227 increase sample sizes when individual teams lack the resources to collect larger sample sizes.
228
Another important way to introduce long-lasting change is by improving the statistical education 229 of current and future scientists 5 . Even though our analyses demonstrate that sufficient power in 230 clinical trials is still problematic, the situation seems to be slowly improving. Together, these 231 results encourage further efforts to increase statistical power in clinical trials to guarantee 232 rigorous and reproducible evidence-based medicine. 
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Years with less than ten studies with the specific measure were omitted from the plot. period is plotted between parentheses following the disciplines' names. are computed based on the meta-analysis; every meta-analysis is taken into account once irrespective of the number of included trials. To obtain a meaningful summary statistic, effect sizes were transformed to be unidirectional: the absolute number of risk differences and standardized mean differences was taken, and for (Peto) odds ratios and risk ratio's effects below one were inversed (1 divided by the effect, e.g. an RR of 0. 
